fbpx Yourgene Health plc - Home
Infectious Disease
Clarigene RUO
Clarigene CE-IVD
Clarigene SARS-CoV-2 CE-IVD
Clarigene™ Feature Notes
NIPT
IONA® Nx
For Clinical Laboratories
Overview
Workflow
Clinical Performance
Benefits of the IONA® Nx NIPT Workflow
Instruments
IONA® Software
Atlas Workflow Manager
MyNIPT®
Technical Support
Quality and Regulatory
Choose IONA® Nx NIPT Workflow
the IONA® test
For Clinical Laboratories
Overview
Technology
CE-IVD
Clinical Performance
Results
MyNIPT®
Application Support
FAQs
Choose IONA®
Laboratory Customer Login
For Pregnant Women
For Healthcare Professionals
Overview
Background
Clinical Performance
Results
MyNIPT®
Who can have the IONA® Test
FAQs
Responsible Screening
Choose IONA®
Resources
Contact Us
Sage™ Prenatal Screen
For Clinical Laboratories
Overview
Technology
Clinical Performance
Results
Choose Sage™
Sage QS 32plex
For Pregnant Women
Advantages of the Sage™ prenatal screen
Overview
Who can have the Sage™ test
Results
For Healthcare Professionals
Overview
Background
Who can have the Sage™ test
Clinical Performance
Results
Clinical Performance
Results
Contact Us
Reproductive Health
Cystic Fibrosis
Cystic Fibrosis Analysis
Choose CF-EU2
Male Infertility
Pregnancy Loss
Rapid Aneuploidy Analysis
QST*R Range
QST*R Feature Notes
Thrombosis Risk Panel
Precision Medicine
Elucigene DPYD
DPYD Overview
DPYD Testing Workflow
Clinical Performance
Choose Elucigene DPYD
Yourgene Flex™
DNA Size Selection / Enrichment
Ranger Technology
LightBench®
Overview
Get to the DNA you care about in NIPT
Get to the DNA you care about in Liquid Biopsy
NGS QC
LightBench® Feature Notes
Yourgene® QS250
Yourgene® SP150

A CE-Marked RT-qPCR assay which detects the presence of  SARS-CoV-2 viral RNA

4 bubbles clarigene

Benefits

  • High accuracy with >99.9% specificity*
  • Clinical sample testing presented 100% concordance when compared to gold standard reference**
  • Excellent sensitivity and precision (LOD of 5 copies per reaction); results are in concordance with an international external quality assessment panel
  • Dual viral RNA targets; SARS CoV–2 Envelope gene and Nucleocapsid (N) gene for a more reliable result
  • Assay uses N and E gene targets which are SARS-CoV-2 specific, meaning no cross reactivity with other Coronaviruses
  • Human RNase P control designed as a true RNA control for lower false negatives
  • Internal control detects improper sample collection or poor-quality sample to give an invalid result, rather than giving a negative result
  • Fast turnaround time after RNA extraction
  • Simple and easy to set up
  • High throughput options available

*In silico analysis did not identify any potentially amplifiable targets in other respiratory pathogens.

** 48/48 positive and 24/24 negative

For information regarding our ongoing rigorous viral surveillance program please see here.

 

Performance of the Clarigene assay is not impacted by the following viral strain variants:
 LineageVariant of Concern NamingAssociated Country/Region
B.1.1.7

20I/501Y.V1 AKA 202012/01

UK (Alpha variant)

B.1.351

20H/501Y.V2

South Africa (Beta variant)

P.1/ B.1.1.28

20J/501Y.V3

Brazil (Gamma variant)

B.1.429

 20C/S:452R

USA (California)

B.1.617

 20A/S:478K

India (Delta variant)

Specifications

  • Kit includes Mastermix, run controls, ROX, primers and probes
  • Compatible with RNA extracted from nasopharyngeal swabs
  • Assay can be easily adapted to robotic liquid handling (automated version to follow)
  • 960 tests per kit for high throughput testing
  • Compatible with qPCR machines capable of detection of FAM, VIC and Cy5 fluorophores

Why Choose Clarigene™

  • Low False Negatives

    Tests must include fail-safe controls that affirmatively report the presence of intact RNA and demonstrate success of all steps of the assay. A result of “no virus signal” is insufficient for clinical interpretation: controls must also say “The reaction worked as intended and would have found virus if present”. Many assays on the market use a RNase P control designed within a single exon and so detect both reverse-transcribed RNA and human genomic DNA, i.e., are unable to differentiate human genomic DNA from reverse-transcribed RNA. This inability can lead to false negative results where reverse transcription fails, but human DNA is amplified and interpreted as a successful, SARS-CoV-2 negative, test. Yourgene RNase P control is designed to span an exon boundary and hence does not detect human genomic DNA so is a true RNA control.

  • High Accuracy

    N target is specific for SARS-CoV-2 and does not cross react with other Coronaviruses unlike some other assays on the market.

  • Fast Turnaround Time

    Automation compatible kit format (CE-IVD) with easy to interpret data.

  • Post-market surveillance

    Yourgene has an ongoing rigorous surveillance programme. As new variants are identified, the Company conducts both detailed in silico (computer) analysis and wet lab testing of the mutations to assess the reliability of the Clarigene SARS-CoV-2 test and will confirm any impact once results are in.

Clarigene™ SARS-CoV-2 assay publications

  1. Curr Trends Med Diagn Meth. 2021 Feb 4. DOI: 10.29011/CTMDM.100110. Novel CE-Marked SARS-CoV-2 IVD Assay Solves the Problem for Genomic DNA Contamination. Ilieva VI, Flynn EM, Marvin JMC, Szynkiewicz M, Morrissey C, et al.

Ordering Information

 Product CodeKit Size 
CLCV2B96   96 reactions per kit
CLCV2BK  960 reactions per kit

 

Clarigene™ logoClick here to read in Current Trends in Medical Diagnostic Methods: Novel CE-Marked SARS-CoV-2 IVD assay solves the problem for genomic DNA contaminationCOVID-19 virus cell